Charlotte Charpentier

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5478491/publications.pdf

Version: 2024-02-01

201 papers	4,125 citations	126907 33 h-index	182427 51 g-index
217 all docs	217 docs citations	217 times ranked	4928 citing authors

#	Article	IF	Citations
1	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infectious Diseases, The, 2016, 16, 565-575.	9.1	217
2	The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. Journal of Infection, 2021, 83, e1-e3.	3.3	146
3	2019 update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine, 2019, 27, 111-121.	0.1	127
4	Contribution of Recombination to the Evolution of Human Immunodeficiency Viruses Expressing Resistance to Antiretroviral Treatment. Journal of Virology, 2007, 81, 7620-7628.	3.4	103
5	Extensive Recombination among Human Immunodeficiency Virus Type 1 Quasispecies Makes an Important Contribution to Viral Diversity in Individual Patients. Journal of Virology, 2006, 80, 2472-2482.	3.4	102
6	Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy*. HIV Medicine, 2008, 9, 765-770.	2.2	95
7	Omicron SARS-CoV-2 variant: What we know and what we donâ€™t. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 100998.	1.4	93
8	Hiv-2 molecular epidemiology. Infection, Genetics and Evolution, 2016, 46, 233-240.	2.3	86
9	Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease Inhibitors. Journal of Virology, 2004, 78, 4234-4247.	3.4	76
10	Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors. MBio, 2017, 8, .	4.1	71
11	Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). Journal of Antimicrobial Chemotherapy, 2019, 74, 739-745.	3.0	67
12	Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study. Antimicrobial Agents and Chemotherapy, 2010, 54, 3335-3340.	3.2	65
13	Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. Journal of Antimicrobial Chemotherapy, 2010, 65, 2620-2627.	3.0	62
14	Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016. PLoS ONE, 2017, 12, e0180888.	2.5	55
15	Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1507-1512.	3.0	52
16	Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives. Clinical Microbiology and Infection, 2021, 27, 789.e1-789.e5.	6.0	52
17	Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. Journal of Thoracic Oncology, 2022, 17, 239-251.	1.1	51
18	Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure. Antimicrobial Agents and Chemotherapy, 2009, 53, 4522-4524.	3.2	46

#	Article	IF	Citations
19	Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients. Antimicrobial Agents and Chemotherapy, 2008, 52, 3237-3243.	3.2	45
20	Molecular Determinants of HIV-2 R5-X4 Tropism in the V3 Loop: Development of a New Genotypic Tool. Journal of Infectious Diseases, 2012, 205, 111-120.	4.0	44
21	The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. Journal of Antimicrobial Chemotherapy, 2011, 66, 2827-2830.	3.0	43
22	Genotypic resistance profiles of HIV-2-treated patients in West Africa. Aids, 2014, 28, 1161-1169.	2.2	43
23	Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy. Aids, 2015, 29, 1665-1671.	2.2	43
24	Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses. Journal of Antimicrobial Chemotherapy, 2013, 68, 1237-1242.	3.0	42
25	HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007â€“12: impact on susceptibility to first-line strategies. Journal of Antimicrobial Chemotherapy, 2015, 70, 2084-2089.	3.0	42
26	Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome. Journal of Antimicrobial Chemotherapy, 2012, 67, 2231-2235.	3.0	41
27	National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. Journal of Antimicrobial Chemotherapy, 2013, 68, 2626-2631.	3.0	41
28	HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravirâ€‰+â€‰lamivudine in the maintenance DOLULAM pilot study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2831-2836.	3.0	41
29	Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort. Journal of Antimicrobial Chemotherapy, 2019, 74, 754-760.	3.0	41
30	Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen. Journal of Antimicrobial Chemotherapy, 2018, 73, 1039-1044.	3.0	40
31	High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. Aids, 2010, 24, 867-873.	2.2	38
32	Residual HIV-1 RNA and HIV-1 Dna Production in the Genital Tract Reservoir of Women Treated with Haart: The Prospective Anrs Ep24 Gynodyn Study. Antiviral Therapy, 2011, 16, 843-852.	1.0	36
33	New insights in COVID-19â€“associated chilblains: A comparative study with chilblain lupus erythematosus. Journal of the American Academy of Dermatology, 2020, 83, 1219-1222.	1.2	36
34	Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients. Antimicrobial Agents and Chemotherapy, 2010, 54, 72-77.	3.2	33
35	High Rate Of Antiretroviral Drug Resistance Mutations in HIV Type 1-Infected Senegalese Children in Virological Failure on First-Line Treatment According to the World Health Organization Guidelines. AIDS Research and Human Retroviruses, 2013, 29, 242-249.	1.1	33
36	Influence of gas atmosphere (Ar or He) on the laser powder bed fusion of a Ni-based alloy. Journal of Materials Processing Technology, 2021, 288, 116851.	6.3	33

#	Article	IF	Citations
37	High Frequency of Antiretroviral Drug Resistance among HIVâ€Infected Adults Receiving Firstâ€Line Highly Active Antiretroviral Therapy in Nâ€™Djamena, Chad. Clinical Infectious Diseases, 2009, 49, 155-159.	5.8	31
38	In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. Aids, 2010, 24, 2753-2755.	2.2	31
39	Virological Response and Resistance Profiles After 18 to 30 Months of First- or Second-/Third-Line Antiretroviral Treatment: A Cross-Sectional Evaluation in HIV Type 1-Infected Children Living in the Central African Republic. AIDS Research and Human Retroviruses, 2012, 28, 87-94.	1.1	31
40	HIV-2EU: Supporting Standardized HIV-2 Drug Resistance Interpretation in Europe. Clinical Infectious Diseases, 2013, 56, 1654-1658.	5.8	31
41	Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program. Clinical Infectious Diseases, 2015, 60, 1521-7.	5.8	30
42	Hot Spots of Integrase Genotypic Changes Leading to HIV-2 Resistance to Raltegravir. Antimicrobial Agents and Chemotherapy, 2011, 55, 1293-1295.	3.2	29
43	Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients. Journal of Antimicrobial Chemotherapy, 2020, 75, 1588-1590.	3.0	29
44	Gag Mutations Can Impact Virological Response to Dual-Boosted Protease Inhibitor Combinations in Antiretroviral-Naiˆve HIV-Infected Patients. Antimicrobial Agents and Chemotherapy, 2010, 54, 2910-2919.	3.2	28
45	In VitroPhenotypic Susceptibility of HIV-2 Clinical Isolates to CCR5 Inhibitors. Antimicrobial Agents and Chemotherapy, 2012, 56, 137-139.	3.2	28
46	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine, 2017, 18, 225-235.	6.1	28
47	Pharmacokinetics of Dolutegravir in a Premature Neonate after HIV Treatment Intensification during Pregnancy. Antimicrobial Agents and Chemotherapy, 2015, 59, 3660-3662.	3.2	27
48	Prevalence of HIV-1 drug resistance in treated patients with viral load >50Âcopies/mL: a 2014 French nationwide study. Journal of Antimicrobial Chemotherapy, 2017, 72, 1769-1773.	3.0	27
49	Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load. Journal of Clinical Virology, 2017, 96, 49-53.	3.1	27
50	Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations. Viruses, 2018, 10, 41.	3.3	27
51	Early archives of genetically-restricted proviral DNA in the female genital tract after heterosexual transmission of HIV-1. Aids, 2007, 21, 153-162.	2.2	26
52	Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients. Journal of Antimicrobial Chemotherapy, 2017, 72, 2954-2955.	3.0	26
53	Virological Response and Resistance Profiles After 24 Months of First-Line Antiretroviral Treatment in Adults Living in Bangui, Central African Republic. AIDS Research and Human Retroviruses, 2012, 28, 315-323.	1.1	25
54	Prevalence of Human Papillomavirus, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo: A National Cross-sectional Survey. Clinical Infectious Diseases, 2019, 69, 1019-1026.	5.8	25

#	Article	IF	Citations
55	Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients. Journal of Antimicrobial Chemotherapy, 2012, 67, 1459-1461.	3.0	24
56	Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. Journal of Antimicrobial Chemotherapy, 2012, 67, 1475-1478.	3.0	24
57	Association of Soluble CD14 and Inflammatory Biomarkers With HIV-2 Disease Progression. Clinical Infectious Diseases, 2012, 55, 1417-1425.	5.8	24
58	Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure. Journal of Clinical Virology, 2010, 47, 79-81.	3.1	23
59	High Prevalence of Antiretroviral Drug Resistance among HIV-1-Untreated Patients in Guinea-Conakry and in Niger. Antiviral Therapy, 2011, 16, 429-433.	1.0	23
60	Characterization of CRF56_cpx, a new circulating B/CRF02/G recombinant form identified in MSM in France. Aids, 2013, 27, 2309-2312.	2.2	23
61	Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response. Journal of Antimicrobial Chemotherapy, 2015, 70, 2090-2096.	3.0	23
62	HIV-2EUâ€"Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update: Table 1.. Clinical Infectious Diseases, 2015, 61, 1346-1347.	5.8	23
63	First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). Clinical Infectious Diseases, 2018, 67, 1161-1167.	5.8	23
64	Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. Journal of Antimicrobial Chemotherapy, 2019, 74, 614-617.	3.0	23
65	A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain. Clinical Infectious Diseases, 2019, 69, 657-667.	5.8	22
66	Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study. Journal of Antimicrobial Chemotherapy, 2020, 75, 3344-3348.	3.0	22
67	Evaluation of three extraction-free SARS-CoV-2 RT-PCR assays: A feasible alternative approach with low technical requirements. Journal of Virological Methods, 2021, 291, 114086.	2.1	22
68	Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott). Journal of Clinical Virology, 2020, 132, 104618.	3.1	22
69	Usefulness of multiplex PCR methods and respiratory virusesâ€™ distribution in children below 15 years old according to age, seasons and clinical units in France: A 3 years retrospective study. PLoS ONE, 2017, 12, e0172809.	2.5	21
70	Prevalence of human papillomavirus, human immunodeficiency virus and other sexually transmitted infections among female sex workers in Togo: a national cross-sectional survey. Clinical Microbiology and Infection, 2019, 25, 1560.e1-1560.e7.	6.0	21
71	Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. Journal of Antimicrobial Chemotherapy, 2020, 75, 1026-1030.	3.0	20
72	Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure. Transplant Infectious Disease, 2010, 12, 213-219.	1.7	19

#	Article	IF	Citations
73	Baseline Genotypic and Phenotypic Susceptibilities of HIV-1 Group O to Enfuvirtide. Antimicrobial Agents and Chemotherapy, 2010, 54, 4016-4019.	3.2	19
74	Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing. Journal of Antimicrobial Chemotherapy, 2018, 73, 2485-2492.	3.0	19
75	Low Genetic Barrier to Large Increases in HIV-1 Cross-Resistance to Protease Inhibitors during Salvage Therapy. Antiviral Therapy, 2006, 11, 143-154.	1.0	19
76	Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2014, 69, 1086-1089.	3.0	18
77	Budget impact of antiretroviral therapy in a French clinic cohort. Aids, 2017, 31, 1271-1279.	2.2	17
78	Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen. Aids, 2010, 24, 2651-2656.	2.2	16
79	M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients. Journal of Antimicrobial Chemotherapy, 2020, 75, 1290-1293.	3.0	16
80	Mutation V111I in HIV-2 Reverse Transcriptase Increases the Fitness of the Nucleoside Analogue-Resistant K65R and Q151M Viruses. Journal of Virology, 2015, 89, 833-843.	3.4	15
81	Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. Clinical Infectious Diseases, 2018, 66, 1588-1594.	5.8	15
82	Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. Journal of Antimicrobial Chemotherapy, 2008, 61, 1362-1368.	3.0	14
83	Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism. Journal of Antimicrobial Chemotherapy, 2011, 66, 1972-1975.	3.0	14
84	Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010. Journal of Antimicrobial Chemotherapy, 2013, 68, 2197-8.	3.0	14
85	Intensification of Antiretroviral Therapy through Addition of Enfuvirtide in Naive HIV-1-Infected Patients with Severe Immunosuppression Does Not Improve Immunological Response: Results of a Randomized Multicenter Trial (ANRS 130 Apollo). Antimicrobial Agents and Chemotherapy, 2013, 57, 758-765.	3.2	14
86	Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study. Journal of Antimicrobial Chemotherapy, 2015, 70, 1881-1884.	3.0	14
87	Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a caseâ€“control study. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw527.	3.0	14
88	Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir. Journal of Antimicrobial Chemotherapy, 2018, 73, 2716-2720.	3.0	14
89	Prevalence of genotypic baseline risk factors for cabotegravirâ€Š+â€Šrilpivirine failure among ARV-naive patients. Journal of Antimicrobial Chemotherapy, 2021, 76, 2983-2987.	3.0	14
90	Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial. Journal of Antimicrobial Chemotherapy, 2013, 68, 690-696.	3.0	13

#	Article	IF	Citations
91	Evaluation of Four Tenofovir-Containing Regimens as First-Line Treatments in Cameroon and Senegal: The Anrs 12115 Dayana Trial. Antiviral Therapy, 2014, 19, 51-59.	1.0	13
92	High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort. Journal of Antimicrobial Chemotherapy, 2018, 73, 1665-1671.	3.0	13
93	No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. Journal of Antimicrobial Chemotherapy, 2018, 73, 173-176.	3.0	13
94	Human Immunodeficiency Virusâ€"2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western Europe. Clinical Infectious Diseases, 2021, 72, 503-509.	5.8	13
95	In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20). Journal of Antimicrobial Chemotherapy, 2009, 64, 1192-1195.	3.0	12
96	Usefulness of a genotypic resistance test using dried blood spot specimens in African HIV-infected children with virological failure according to the 2010-revised WHO criteria. Archives of Virology, 2011, 156, 1603-1606.	2.1	12
97	Transmitted drug resistance in French HIV-2-infected patients. Aids, 2013, 27, 1671-1674.	2.2	12
98	Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes. Journal of Antimicrobial Chemotherapy, 2015, 70, 130-135.	3.0	12
99	Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A caseâ€series experience. Journal of Medical Virology, 2016, 88, 1204-1210.	5.0	12
100	Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France. Journal of Antimicrobial Chemotherapy, 2019, 74, 1417-1424.	3.0	12
101	Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (Marchâ€"May 2020). Clinical Microbiology and Infection, 2021, 27, 1520.e1-1520.e5.	6.0	12
102	Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2011, 66, 1582-1589.	3.0	11
103	High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients. Aids, 2015, 29, 779-784.	2.2	11
104	Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort. Journal of Antimicrobial Chemotherapy, 2017, 72, 1745-1751.	3.0	11
105	Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients. Journal of Antimicrobial Chemotherapy, 2019, 74, 1368-1375.	3.0	11
106	Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting. Journal of Antimicrobial Chemotherapy, 2021, 77, 196-204.	3.0	11
107	A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encoding the P-glycoprotein. Human Mutation, 2000, 15, 486-486.	2.5	10
108	Positive Impact of HIV-1gagCleavage Site Mutations on the Virological Response to Darunavir Boosted with Ritonavir. Antimicrobial Agents and Chemotherapy, 2011, 55, 1754-1757.	3.2	10

#	Article	IF	Citations
109	Virological Failure and HIV Type 1 Drug Resistance Profiles Among Patients Followed-up in Private Sector, Douala, Cameroon. AIDS Research and Human Retroviruses, 2011, 27, 221-230.	1.1	10
110	Presence of Human Papillomavirus (HPV) Apolipoprotein B Messenger RNA Editing, Catalytic Polypeptide-Like 3 (APOBEC)â€“Related Minority Variants in HPV-16 Genomes From Anal and Cervical Samples but Not in HPV-52 and HPV-58. Journal of Infectious Diseases, 2018, 218, 1027-1036.	4.0	10
111	Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Datâ€™AIDS Cohort Study. Clinical Infectious Diseases, 2020, 71, 2880-2888.	5.8	10
112	Predictive Value of Liver Enzymes and Inflammatory Biomarkers for the Severity of Liver Fibrosis Stage in HIV/HCV Co-Infected Patients. PLoS ONE, 2013, 8, e59205.	2.5	10
113	Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients. Journal of Clinical Virology, 2008, 43, 212-215.	3.1	9
114	Surveillance of Antiretroviral Drug Resistance Mutations in Untreated Young Children Living in the Central African Republic. Antiviral Therapy, 2011, 16, 1347-1350.	1.0	9
115	Update on the Human Immunodeficiency Virus. MÃ©decine Et Maladies Infectieuses, 2013, 43, 177-184.	5.0	9
116	Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay. Journal of Antimicrobial Chemotherapy, 2014, 69, 2819-2825.	3.0	9
117	Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy. Journal of Antimicrobial Chemotherapy, 2015, 70, 1517-1521.	3.0	9
118	Disparities in <scp>HIV</scp>â€1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations. HIV Medicine, 2017, 18, 696-700.	2.2	9
119	Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants. PLoS ONE, 2018, 13, e0198334.	2.5	9
120	Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravirâ€‰+â€‰lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial). Journal of Antimicrobial Chemotherapy, 2020, 75, 1611-1617.	3.0	9
121	Distribution of HIV-1 and HSV-2 epidemics in Chad revealing HSV-2 hot-spot in regions of high-risk HIV spread. Journal of Infection in Developing Countries, 2011, 5, 064-067.	1.2	9
122	Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal. Antiviral Therapy, 2011, 16, 937-940.	1.0	8
123	Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?. Journal of Antimicrobial Chemotherapy, 2020, 75, 183-193.	3.0	8
124	Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection. PLoS Pathogens, 2019, 15, e1007758.	4.7	8
125	New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. Journal of Antimicrobial Chemotherapy, 2019, 74, 2019-2023.	3.0	8
126	HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. Journal of Antimicrobial Chemotherapy, 2019, 74, 1679-1692.	3.0	8

#	Article	IF	Citations
127	Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012â€“2018. Clinical Infectious Diseases, 2021, 73, e3266-e3274.	5.8	8
128	Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy. Scandinavian Journal of Infectious Diseases, 2011, 43, 373-379.	1.5	7
129	Long-term follow-up of 11 protease inhibitor (PI)-naÃ¯ve and PI-treated HIV-infected patients harbouring virus with insertions in the HIV-1 protease gene. HIV Medicine, 2011, 12, 138-144.	2.2	7
130	Combinatorial prevention of HIV transmission in women: the case for a vaginal microbicide. Future Microbiology, 2011, 6, 731-737.	2.0	7
131	Natural evolution of CD4+ cell count in patients with CD4 >350 or >500â€‰cells/mm³ at the time of diagnosis according to HIVâ€‘1 coreceptor tropism. Journal of Medical Virology, 2012, 84, 1853-1856.	5.0	7
132	Longitudinal analysis of integrase <scp>N</scp>155<scp>H</scp> variants in heavily treated patients failing raltegravirâ€based regimens. HIV Medicine, 2013, 14, 85-91.	2.2	7
133	Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. Aids, 2013, 27, 292-295.	2.2	7
134	Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors. Journal of Antimicrobial Chemotherapy, 2013, 68, 2199-2204.	3.0	7
135	Short Communication: Prevalence of HIV-1 Transmitted Drug Resistance in Liberia. AIDS Research and Human Retroviruses, 2014, 30, 863-866.	1.1	7
136	Virological failure of patients on maraviroc-based antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2015, 70, 1858-64.	3.0	7
137	HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors. Journal of Antimicrobial Chemotherapy, 2017, 72, 2431-2437.	3.0	7
138	Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates. PLoS ONE, 2015, 10, e0134904.	2.5	7
139	Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients. Aids, 2013, 27, 69-80.	2.2	6
140	In-vitro phenotypic susceptibility of HIV-1 â€™non-Bâ€™ integrase inhibitors naive clinical isolates to dolutegravir and raltegravir. Aids, 2013, 27, 2959-2961.	2.2	6
141	Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial). PLoS ONE, 2013, 8, e53621.	2.5	6
142	HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients. Aids, 2014, 28, 2160-2162.	2.2	6
143	Sustained virological failure in Cameroonese patient infected by HIV-1 group N evidenced by sequence-based genotyping assay. Aids, 2015, 29, 1267-1269.	2.2	6
144	Tropism distribution among antiretroviral-naive HIV-2-infected patients. Aids, 2015, 29, 2209-2212.	2.2	6

#	Article	IF	Citations
145	Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study. Frontiers in Public Health, 2018, 6, 63.	2.7	6
146	High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO. Journal of Antimicrobial Chemotherapy, 2019, 74, 2030-2038.	3.0	6
147	Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine. Journal of Infection, 2022, 84, 248-288.	3.3	6
148	PD-1/PD-L1 expression in anal squamous intraepithelial lesions. Oncotarget, 2020, 11, 3582-3589.	1.8	6
149	Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 129-133.	2.9	5
150	Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2016, 71, 2651-2653.	3.0	5
151	Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients. Journal of Antimicrobial Chemotherapy, 2018, 73, 1173-1176.	3.0	5
152	HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution. Virus Evolution, 2021, 7, veab024.	4.9	5
153	HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir. Journal of Antimicrobial Chemotherapy, 2021, 76, 2306-2309.	3.0	5
154	Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays. Journal of Infection, 2022, 84, 834-872.	3.3	5
155	Prevalence of hepatitis B and C among female sex workers in Togo, West Africa. PLoS ONE, 2021, 16, e0259891.	2.5	5
156	Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen. Aids, 2011, 25, 2143-2148.	2.2	4
157	Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice. Journal of Antimicrobial Chemotherapy, 2012, 67, 2487-2493.	3.0	4
158	Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective Study. AIDS Research and Human Retroviruses, 2017, 33, 11-16.	1.1	4
159	Score for pulmonary tuberculosis in patients with clinical presumption of tuberculosis in a low-prevalence area. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1272-1279.	1.2	4
160	Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals. Clinical Infectious Diseases, 2018, 66, 1785-1793.	5.8	4
161	Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen. Journal of Antimicrobial Chemotherapy, 2019, 74, 718-721.	3.0	4
162	Kaposi sarcoma among people living with <scp>HIV</scp> in the French <scp>DAT</scp>â€™<scp>AIDS</scp> cohort between 2010 and 2015. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1065-1073.	2.4	4

#	Article	IF	Citations
163	Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey. Journal of Antimicrobial Chemotherapy, 2021, 76, 2400-2406.	3.0	4
164	Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up. PLoS ONE, 2015, 10, e0134430.	2.5	4
165	Alpha (B.1.1.7) and Delta (B.1.617.2 â€“ AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage. Journal of Infection, 2022, 84, 418-467.	3.3	4
166	Multicenter Quality Control of Hepatitis C Virus Protease Inhibitor Resistance Genotyping. Journal of Clinical Microbiology, 2013, 51, 1428-1433.	3.9	3
167	HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. PLoS ONE, 2015, 10, e0127816.	2.5	3
168	HPV 16 in squamous cell carcinoma of 19th century tonsils. Lancet Oncology, The, 2016, 17, e477-e478.	10.7	3
169	Interest of cytology combined with Xpert^{Â®}<scp>HPV</scp> and Anyplex^{Â®}<scp>II HPV</scp>28 Detection human papillomavirus (<scp>HPV</scp>) typing: differential profiles of anal and cervical <scp>HPV</scp> lesions in <scp>HIV</scp>â€infected patients on antiretroviral therapy. HIV Medicine, 2018, 19, 698-707.	2.2	3
170	New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of <scp>HIV</scp>â€1 reverse transcriptase (M184L and M184T). Chemical Biology and Drug Design, 2019, 93, 50-59.	3.2	3
171	Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure. International Journal of Antimicrobial Agents, 2020, 56, 106039.	2.5	3
172	A Comparison of Cell Activation, Exhaustion, and Expression of HIV Coreceptors and Restriction Factors in HIV-1- and HIV-2-Infected Nonprogressors. AIDS Research and Human Retroviruses, 2021, 37, 214-223.	1.1	3
173	Prevalence and factors associated with trichomonas vaginalis infection among female sex workers in Togo, 2017. BMC Infectious Diseases, 2021, 21, 775.	2.9	3
174	Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen. Journal of Antimicrobial Chemotherapy, 2014, 69, 2588-2590.	3.0	2
175	Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response. AIDS Research and Human Retroviruses, 2015, 31, 475-478.	1.1	2
176	HIV-1 diagnosis with unquantifiable viraemia: donâ€™t be naive, look for antiretroviral drugs. Journal of Antimicrobial Chemotherapy, 2017, 72, 630-632.	3.0	2
177	Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS) Tj ETQq1 1 0.784314 rgBT /Overlock 10	3.0	2
178	HIV-2 Primary Infection in a French 69-Year-Old Bisexual Man. Open Forum Infectious Diseases, 2018, 5, ofy223.	0.9	2
179	Use of Combination Systemic-Intratumoral HPV Vaccine to Treat Cutaneous Basaloid Squamous Cell Carcinomas. JAMA Dermatology, 2019, 155, 123.	4.1	2
180	Conventional Dendritic Cells and Slan+ Monocytes During HIV-2 Infection. Frontiers in Immunology, 2020, 11, 1658.	4.8	2

#	Article	IF	Citations
181	Darunavir resistance spectrum in darunavirâ€naáµ¢ve patients harboring virological failure to antiretroviral therapy. Journal of the International AIDS Society, 2010, 13, P133.	3.0	1
182	Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy. Infection and Drug Resistance, 2010, 3, 103.	2.7	1
183	NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatment. Journal of Global Antimicrobial Resistance, 2014, 2, 103-106.	2.2	1
184	Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads. Journal of Virological Methods, 2018, 257, 12-15.	2.1	1
185	HIV Infection in North African Patients. AIDS Research and Human Retroviruses, 2019, 35, 628-633.	1.1	1
186	Was Zika introduced to Brazil by participants at the 2013 Beach Soccer World Cup held in Tahiti: A phylogeographical analysis. Travel Medicine and Infectious Disease, 2019, 32, 101512.	3.0	1
187	Occurrence of Extensive Cutaneous Human Papillomavirus Infection After Initiation of Tofacitinib Therapy. JAMA Dermatology, 2019, 155, 629.	4.1	1
188	New insights are game-changers in HIV-2 disease management. Lancet HIV,the, 2019, 6, e214.	4.7	1
189	Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote dâ€™Ivoire West Africa. PLoS ONE, 2020, 15, e0236642.	2.5	1
190	Description of the L76V Resistance Protease Mutation in HIV-1 B and â€œNon-Bâ€•Subtypes. PLoS ONE, 2013, 8, e54381.	2.5	1
191	Pitfalls of antiretroviral drug resistance genotyping of HIV-1 Group M and Group N from Cameroon by sequenced-based assays. Nigerian Medical Journal, 2015, 56, 420.	0.6	1
192	In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions. Journal of Antimicrobial Chemotherapy, 2021, , .	3.0	1
193	Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens. Journal of the International AIDS Society, 2010, 13, P136-P136.	3.0	0
194	Variants rÃ©sistants minoritaires VIHÂ: dÃ©tection, prÃ©valence et impact sur la rÃ©ponse virologique. Journal Des Anti-infectieux, 2012, 14, 20-26.	0.1	0
195	Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment. Journal of the International AIDS Society, 2014, 17, 19744.	3.0	0
196	Politique des unitÃ©s de rÃ©animation pÃ©diatrique francophones concernant lâ€™admission des adolescents. AnesthÃ©sie & RÃ©animation, 2015, 1, 540-546.	0.1	0
197	DiversitÃ© gÃ©nÃ©tique des papillomavirus humains. Journal Des Anti-infectieux, 2017, 19, 125-133.	0.1	0
198	Short Communication: Extremely Severe CD4 Lymphopenia During HIV-1 Primary Infection. AIDS Research and Human Retroviruses, 2019, 35, 930-933.	1.1	0

#	Article	IF	Citations
199	Contribution of rapid lateral flow assays from capillary blood specimens to the diagnosis of COVID-19 in symptomatic healthcare workers: a pilot study in a university hospital, Paris, France. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115430.	1.8	0
200	Purifying Selection in Human Immunodeficiency Virus-1 pol Gene in Perinatally Human Immunodeficiency Virus-1-Infected Children Harboring Discordant Immunological Response and Virological Nonresponse to Long-Term Antiretroviral Therapy. Journal of Clinical Medicine Research, 2020, 12, 369-376.	1.2	0
201	Humoral Response to SARS-CoV-2 mRNA Vaccine in Heart Transplant Recipients up to 4 Months After the Third Vaccine Injection. Journal of Heart and Lung Transplantation, 2022, 41, S277-S278.	0.6	0